Agenus (NASDAQ:AGEN) Stock Keeps Buy Rating at Chardan CapitalMarket Beat·Oct 22, 2026 at 12:42 PM00847G8040.00%AGEN-2.76%
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer TrialMarket Beat·Oct 20, 2026 at 09:02 PM00847G8040.00%AGEN-2.76%
AGEN: ROBBIN’s neoadjuvant trial is the central catalyst, with first enrollment expected in Q1 2027Quartr·Oct 20, 2026 at 06:05 PM00847G8040.00%AGEN-2.76%
Agenus Inc. (AGEN) - What Are Investment Firms Saying About This Stock?Market Beat·Oct 13, 2026 at 12:44 PM00847G8040.00%AGEN-2.76%
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference | AGEN Stock NewsStockTitan·Oct 9, 2026 at 11:23 AM00847G8040.00%AGEN-2.76%
Agenus Inc. (AGEN) Wins First Marketing OKs for BOT+BAL in ArmeniaTradingView·Oct 8, 2026 at 11:30 AM00847G8040.00%AGEN-2.76%
Chardan Capital maintains Buy rating on Agenus, $40 price targetTradingView·Oct 5, 2026 at 12:22 PM00847G8040.00%AGEN-2.76%
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 | AGEN Stock NewsStockTitan·Oct 3, 2026 at 06:50 AM00847G8040.00%AGEN-2.76%
Agenus presents long-term survival data for botensilimab-balstilimab in MSS metastatic colorectal cancer at SITC 2026PUBT·Oct 2, 2026 at 01:01 PM00847G8040.00%AGEN-2.76%
